A Phase 2/3 Safety, Pharmacokinetics, and Efficacy Study of Nirmatrelvir/Ritonavir in Pediatric, Nonhospitalized Symptomatic Participants With COVID-19 Who Are at Risk of Progression to Severe Disease

Study Description

We are conducting a research study to evaluate the safety, pharmacokinetics and efficacy of orally administered study drug for the treatment of nonhospitalized, symptomatic pediatric participants with COVID-19 who are at risk of progression of severe disease. This study may include multiple visits. Upon completion of the study visit(s), you will be paid for your time.

Study Eligibility

Male or female participants:

Cohort 1: Weight: greater than or equal to 88 lbs

Age Group:

• 12 year age to less than 18 year age
• 6 year age to less than 12 year age

Cohort 2: Weight: greater than or equal to 44 lbs to less than 88 lbs

Age Group:

• Greater than or equal to 6 year age to less than 18 year age

Cohort 3: Age Group: 2 year age to less than 6 year age

Cohort 4: Age Group: 1 month age to less than 2 year age

Cohort 5: Age Group: less than 1 month age

Contact Information

For more information about this study, contact Ankita Patel at 501-364-1065 or Steven Giompoletti at 501-364-2794